Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcopenia | 2 | 2023 | 368 | 0.790 |
Why?
|
| Neuroma, Acoustic | 1 | 2022 | 451 | 0.630 |
Why?
|
| Cerebellar Neoplasms | 1 | 2022 | 587 | 0.610 |
Why?
|
| Medulloblastoma | 1 | 2022 | 683 | 0.590 |
Why?
|
| Brain Neoplasms | 7 | 2022 | 8863 | 0.500 |
Why?
|
| Hearing Loss | 1 | 2022 | 765 | 0.500 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 1061 | 0.490 |
Why?
|
| Rectal Neoplasms | 1 | 2022 | 1206 | 0.450 |
Why?
|
| Radiosurgery | 1 | 2022 | 1329 | 0.420 |
Why?
|
| Cranial Irradiation | 3 | 2019 | 401 | 0.370 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 20822 | 0.290 |
Why?
|
| Temporal Muscle | 1 | 2023 | 37 | 0.230 |
Why?
|
| Growth Charts | 1 | 2023 | 61 | 0.230 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2021 | 1624 | 0.200 |
Why?
|
| Protons | 2 | 2022 | 1127 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2023 | 3479 | 0.160 |
Why?
|
| Bibliometrics | 1 | 2022 | 339 | 0.160 |
Why?
|
| Hearing | 1 | 2022 | 482 | 0.160 |
Why?
|
| Truth Disclosure | 1 | 2022 | 436 | 0.160 |
Why?
|
| Retrospective Studies | 12 | 2023 | 77449 | 0.150 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 11031 | 0.150 |
Why?
|
| Parotid Gland | 1 | 2017 | 168 | 0.140 |
Why?
|
| Taxoids | 2 | 2017 | 666 | 0.140 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 6895 | 0.140 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 2728 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2023 | 990 | 0.130 |
Why?
|
| Organs at Risk | 1 | 2017 | 346 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2023 | 1524 | 0.130 |
Why?
|
| Doxorubicin | 2 | 2017 | 2234 | 0.110 |
Why?
|
| Prognosis | 6 | 2019 | 29063 | 0.110 |
Why?
|
| Dacarbazine | 1 | 2015 | 566 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 5221 | 0.100 |
Why?
|
| Radiotherapy Dosage | 4 | 2021 | 2879 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 627 | 0.100 |
Why?
|
| Temporal Lobe | 1 | 2019 | 1670 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2022 | 8642 | 0.090 |
Why?
|
| Humans | 23 | 2023 | 744343 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6538 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 2734 | 0.090 |
Why?
|
| Communication | 1 | 2022 | 3749 | 0.080 |
Why?
|
| Neoplasms | 3 | 2022 | 21683 | 0.070 |
Why?
|
| Health Personnel | 1 | 2020 | 3218 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 7913 | 0.070 |
Why?
|
| Research Design | 1 | 2022 | 5987 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 13102 | 0.070 |
Why?
|
| Adult | 7 | 2022 | 214055 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 5319 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2022 | 39050 | 0.060 |
Why?
|
| Middle Aged | 10 | 2023 | 213383 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9239 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2020 | 4371 | 0.060 |
Why?
|
| Aged | 7 | 2023 | 163280 | 0.060 |
Why?
|
| Glioblastoma | 2 | 2015 | 3481 | 0.060 |
Why?
|
| Pandemics | 2 | 2022 | 8388 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 12354 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2023 | 349 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 25043 | 0.050 |
Why?
|
| Quality of Life | 1 | 2023 | 12804 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11524 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2022 | 23338 | 0.050 |
Why?
|
| Male | 10 | 2023 | 350118 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 57776 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2019 | 10252 | 0.050 |
Why?
|
| Female | 10 | 2023 | 380194 | 0.040 |
Why?
|
| Time Factors | 2 | 2019 | 40075 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 11124 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2022 | 63114 | 0.040 |
Why?
|
| Photons | 1 | 2021 | 588 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 53288 | 0.040 |
Why?
|
| Rectum | 1 | 2021 | 904 | 0.040 |
Why?
|
| Young Adult | 1 | 2022 | 56430 | 0.030 |
Why?
|
| Obesity | 1 | 2017 | 12745 | 0.030 |
Why?
|
| Adolescent | 1 | 2022 | 85781 | 0.030 |
Why?
|
| Radiation Protection | 1 | 2017 | 419 | 0.030 |
Why?
|
| New York | 1 | 2015 | 886 | 0.030 |
Why?
|
| Prostate | 1 | 2021 | 1774 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 13695 | 0.030 |
Why?
|
| Brain | 1 | 2019 | 26385 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 2297 | 0.020 |
Why?
|
| Age Distribution | 1 | 2015 | 2902 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 2214 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2020 | 2708 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2023 | 40561 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 2924 | 0.020 |
Why?
|
| Mastectomy | 1 | 2016 | 1793 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 3158 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 9959 | 0.020 |
Why?
|
| United States | 2 | 2022 | 69872 | 0.020 |
Why?
|
| Disease Progression | 1 | 2019 | 13284 | 0.010 |
Why?
|
| Algorithms | 1 | 2022 | 13881 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 14722 | 0.010 |
Why?
|
| Survival Rate | 1 | 2015 | 12788 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2019 | 21746 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2017 | 12720 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 19905 | 0.010 |
Why?
|
| Prevalence | 1 | 2015 | 15226 | 0.010 |
Why?
|
| Child | 1 | 2023 | 77709 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 72290 | 0.010 |
Why?
|
Concepts
(100)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(71)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_